<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01948401</url>
  </required_header>
  <id_info>
    <org_study_id>WB28850</org_study_id>
    <nct_id>NCT01948401</nct_id>
  </id_info>
  <brief_title>A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma</brief_title>
  <official_title>A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID-DEPENDENT ASTHMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This interventional, open study will evaluate clinical data in relation to biomarkers in&#xD;
      patients 12 to 75 years of age with severe oral corticosteroid (OCS) - dependent asthma.&#xD;
      Patients with uncontrolled asthma will be offered an additional escalation of OCS at a dose&#xD;
      of 0.5 mg/kg for 7 days. Patients enrolled in this study would be eligible to be enrolled in&#xD;
      a future placebo-controlled intervention study designed to measure the steroid-sparing effect&#xD;
      of lebrikizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum periostin levels</measure>
    <time_frame>up to 95 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma quality of life questionnaire for adults and adolescents aged 12 years and older (AQLQ12+)</measure>
    <time_frame>up to 95 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-13 related biomarker levels</measure>
    <time_frame>up to 95 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function: Forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC)</measure>
    <time_frame>up to 95 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>up to 95 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes: Asthma Control Questionnaire (ACQ-7)</measure>
    <time_frame>up to 95 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Controlled asthma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Uncontrolled asthma with additional OCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Uncontrolled asthma without additional OCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LABA</intervention_name>
    <description>long-acting beta-agonist treatment</description>
    <arm_group_label>Controlled asthma</arm_group_label>
    <arm_group_label>Uncontrolled asthma with additional OCS</arm_group_label>
    <arm_group_label>Uncontrolled asthma without additional OCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticosteroids</intervention_name>
    <description>chronic treatment with oral corticosteroids, high dose inhaled corticosteroids</description>
    <arm_group_label>Controlled asthma</arm_group_label>
    <arm_group_label>Uncontrolled asthma with additional OCS</arm_group_label>
    <arm_group_label>Uncontrolled asthma without additional OCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <description>additional 0.5 mg/kg orally for 7 days</description>
    <arm_group_label>Uncontrolled asthma with additional OCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult and adolescent patients , &gt;/=12 to &lt;/=75 years of age at the time of informed&#xD;
             consent&#xD;
&#xD;
          -  Severe asthma (as defined by GINA step 5 classification of asthma severity) after a&#xD;
             detailed systematic assessment (the BTS UK Difficult Asthma Network assessment model&#xD;
             [Heaney et al 2010] or equivalent) and follow-up by an asthma specialist for at least&#xD;
             six months&#xD;
&#xD;
          -  History of asthma treatment with high doses of inhaled corticosteroids (ICS ) (&gt;/=1500&#xD;
             mcg beclomethasone dipropionate daily, or equivalent) and long-acting beta-2 agonists&#xD;
             (LABAs), with or without an additional controller, for at least six months before&#xD;
             Screening&#xD;
&#xD;
          -  Chronic treatment with maintenance oral corticosteroids (OCS) for at least six months&#xD;
             before the time of informed consent ; (baseline OCS dose: adults 10 to 40 mg/day,&#xD;
             adolescents 5 to 40 mg/day daily dose equivalent)&#xD;
&#xD;
          -  Compliance with OCS therapy will be based on prior detectable levels of serum&#xD;
             prednisolone, cortisol suppression, or observation of Cushingoid appearance consistent&#xD;
             with regular systemic steroid use&#xD;
&#xD;
          -  Diagnosis of refractory asthma (Heaney et al 2010) with OCS dependence on minimal&#xD;
             effective or maximum tolerated dose&#xD;
&#xD;
          -  Confirmed (by chest x-ray) absence of other significant lung disease&#xD;
&#xD;
          -  Documented history of bronchodilator reversibility response of &gt;/=12% and &gt;/=200 mL&#xD;
             within the past 12 months before the time of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline FEV1 &lt;/=39% of predicted&#xD;
&#xD;
          -  Asthma exacerbation (as defined by protocol) within 28 days before the time of&#xD;
             informed consent or during Screening&#xD;
&#xD;
          -  Major episode of infection requiring admission to hospital for &gt;/=24 hours or&#xD;
             treatment with intravenous antibiotics within the 28 days before the time of informed&#xD;
             consent or during Screening or requiring treatment with oral antibiotics within the 14&#xD;
             days before the time of informed consent or during Screening&#xD;
&#xD;
          -  Active parasitic infection or Listeria monocytogenes infection within the 6 months&#xD;
             before the time of informed consent&#xD;
&#xD;
          -  For adults active tuberculosis (TB) requiring treatment within the 12 months before&#xD;
             the time of informed consent (patients are also required to have no recurrence of&#xD;
             symptoms in the 12 months following completion of TB treatment), or for adolescents&#xD;
             history of active TB requiring treatment&#xD;
&#xD;
          -  Known history of severe clinically significant immunodeficiency&#xD;
&#xD;
          -  Evidence of acute or chronic hepatitis or known liver cirrhosis&#xD;
&#xD;
          -  Inadequate liver function&#xD;
&#xD;
          -  Diagnosis or history of malignancy, or current investigation for possible malignancy&#xD;
&#xD;
          -  Other clinically significant medical disease that is uncontrolled despite treatment or&#xD;
             that is likely, in the opinion of the investigator, to require a change in therapy or&#xD;
             affect the ability to participate in the study&#xD;
&#xD;
          -  Current smoker or former smoker with a smoking history of &gt;15 pack-years&#xD;
&#xD;
          -  Current use of an immunomodulatory/immunosuppressive therapy or past use within three&#xD;
             months or five drug half-lives (whichever is longer) before the time of informed&#xD;
             consent&#xD;
&#xD;
          -  Use of a biologic therapy (including omalizumab) at any time during the 4 months&#xD;
             before the time of informed consent&#xD;
&#xD;
          -  History of anaphylaxis with omalizumab treatment or history of anaphylaxis to any&#xD;
             therapeutic biological agent&#xD;
&#xD;
          -  Use of zileuton or roflumilast at any time during the two months before the time of&#xD;
             informed consent&#xD;
&#xD;
          -  Initiation of or change in allergen immunotherapy within three months before the time&#xD;
             of informed consent&#xD;
&#xD;
          -  Treatment with an investigational agent within 30 days of informed consent or 5&#xD;
             half-lives of the investigational agent, whichever is longer&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Body mass index (BMI) &gt;38 kg/m2&#xD;
&#xD;
          -  Body weight &lt;40 kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <zip>G12 0XH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <zip>G21 3UW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hampshire</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>September 6, 2013</study_first_submitted>
  <study_first_submitted_qc>September 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2013</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

